Drug Information

Drug General Information
Drug ID
D07JAI
Former ID
DIB016871
Drug Name
NSC-639829
Synonyms
N-[4-(5-Bromo-2-pyrimidinyloxy)-3-methylphenyl]-N'-[2-(dimethylamino)benzoyl]urea
Drug Type
Small molecular drug
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Phase 1 [544019]
Structure
Download
2D MOL

3D MOL
Formula
C21H20BrN5O3
Canonical SMILES
CC1=C(C=CC(=C1)NC(=O)NC(=O)C2=CC=CC=C2N(C)C)OC3=NC=C(C=<br />N3)Br
InChI
1S/C21H20BrN5O3/c1-13-10-15(8-9-18(13)30-21-23-11-14(22)12-24-21)25-20(29)26-19(28)16-6-4-5-7-17(16)27(2)3/h4-12H,1-3H3,(H2,25,26,28,29)
InChIKey
JNGQUJZDVFZPEN-UHFFFAOYSA-N
PubChem Compound ID
368697
PubChem Substance ID
499862, 5341284, 8916269, 11417632, 14931987, 35288698, 47499105, 51870116, 57402137, 103267962, 103831174, 104561069, 117564767, 117564768, 136000557, 137823556, 139560732, 224943494, 227162876
Target and Pathway
Target(s) Tubulin beta Target Info Modulator [526117], [551871]
KEGG Pathway Phagosome
Gap junction
Pathogenic Escherichia coli infection
NetPath Pathway FSH Signaling Pathway
TCR Signaling Pathway
EGFR1 Signaling Pathway
PANTHER Pathway Cytoskeletal regulation by Rho GTPase
Huntington disease
Reactome Regulation of PLK1 Activity at G2/M Transition
Loss of Nlp from mitotic centrosomes
Recruitment of mitotic centrosome proteins and complexes
Loss of proteins required for interphase microtubule organization?from the centrosome
Anchoring of the basal body to the plasma membrane
WikiPathways Parkin-Ubiquitin Proteasomal System pathway
Pathogenic Escherichia coli infection
Mitotic G2-G2/M phases
References
Ref 544019Phase I Study of Continuous Weekly Dosing of Dimethylamino Benzoylphenylurea (BPU) in Patients with Solid Tumours. Eur J Cancer. 2007 January; 43(1): 78-86.
Ref 526117Solubilization of NSC-639829. Int J Pharm. 2001 Aug 28;225(1-2):41-7.
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.